Importance of Age and Noncontrast-Enhancing Tumor as Biomarkers for Isocitrate Dehydrogenase-Mutant Glioblastoma: A Multicenter Study

• Published in: Journal of computer assisted tomography Vol. 47; no. 4; p. 659
• Main Authors: Uetani, Hiroyuki, Azuma, Minako, Khant, Zaw Aung, Watanabe, Yoshiyuki, Kudo, Kohsuke, Kadota, Yoshihito, Yokogami, Kiyotaka, Takeshima, Hideo, Kuroda, Jun-Ichiro, Shinojima, Naoki, Hamasaki, Tadashi, Mukasa, Akitake, Hirai, Toshinori
• Format: Journal Article
• Language: English
• Published: United States 01.07.2023
• Subjects: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Case-Control Studies; Female; Glioblastoma - diagnostic imaging; Glioblastoma - enzymology; Glioblastoma - genetics; Humans; Isocitrate Dehydrogenase - genetics; Magnetic Resonance Imaging; Male; Middle Aged; Retrospective Studies
• ISSN: 1532-3145
• DOI: 10.1097/RCT.0000000000001456

This study aimed to investigate the most useful clinical and magnetic resonance imaging (MRI) parameters for differentiating isocitrate dehydrogenase (IDH)-mutant and -wildtype glioblastomas in the 2016 World Health Organization Classification of Tumors of the Central Nervous System. This multicenter study included 327 patients with IDH-mutant or IDH-wildtype glioblastoma in the 2016 World Health Organization classification who preoperatively underwent MRI. Isocitrate dehydrogenase mutation status was determined by immunohistochemistry, high-resolution melting analysis, and/or IDH1/2 sequencing. Three radiologists independently reviewed the tumor location, tumor contrast enhancement, noncontrast-enhancing tumor (nCET), and peritumoral edema. Two radiologists independently measured the maximum tumor size and mean and minimum apparent diffusion coefficients of the tumor. Univariate and multivariate logistic regression analyses with an odds ratio (OR) were performed. The tumors were IDH-wildtype glioblastoma in 306 cases and IDH-mutant glioblastoma in 21. Interobserver agreement for both qualitative and quantitative evaluations was moderate to excellent. The univariate analyses revealed a significant difference in age, seizure, tumor contrast enhancement, and nCET ( P < 0.05). The multivariate analysis revealed significant difference in age for all 3 readers (reader 1, odds ratio [OR] = 0.960, P = 0.012; reader 2, OR = 0.966, P = 0.048; reader 3, OR = 0.964, P = 0.026) and nCET for 2 readers (reader 1, OR = 3.082, P = 0.080; reader 2, OR = 4.500, P = 0.003; reader 3, OR = 3.078, P = 0.022). Age and nCET are the most useful parameters among the clinical and MRI parameters for differentiating IDH-mutant and IDH-wildtype glioblastomas.